Nonrandomized trial evaluates the safety and efficacy of darolutamide with concomitant lipid-modifying agents in nonmetastatic castration-resistant prostate cancer, highlighting combination safety.
This nonrandomized clinical trial assesses the safety and efficacy of darolutamide, with or without concomitant lipid-modifying agents (LMAs), in treating nonmetastatic castration-resistant prostate cancer.
No takes yet. Share an insight, caveat, or question.
Luz et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: